The Manufacturers Life Insurance Company Has $1.28 Million Holdings in 10x Genomics, Inc. (NASDAQ:TXG)

The Manufacturers Life Insurance Company lessened its stake in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 32.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 88,820 shares of the company's stock after selling 42,950 shares during the quarter. The Manufacturers Life Insurance Company owned approximately 0.07% of 10x Genomics worth $1,275,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of TXG. Aquatic Capital Management LLC acquired a new stake in shares of 10x Genomics during the fourth quarter worth $1,853,000. Birchview Capital LP grew its position in shares of 10x Genomics by 66.7% during the 4th quarter. Birchview Capital LP now owns 50,000 shares of the company's stock valued at $718,000 after buying an additional 20,000 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in 10x Genomics during the fourth quarter worth about $1,533,000. Three Seasons Wealth LLC bought a new position in 10x Genomics in the fourth quarter worth about $444,000. Finally, Nebula Research & Development LLC lifted its holdings in 10x Genomics by 74.5% in the fourth quarter. Nebula Research & Development LLC now owns 22,782 shares of the company's stock worth $327,000 after acquiring an additional 9,724 shares during the last quarter. Institutional investors own 84.68% of the company's stock.

Analyst Ratings Changes

TXG has been the topic of a number of research reports. UBS Group dropped their price target on 10x Genomics from $14.00 to $12.00 and set a "neutral" rating on the stock in a research report on Tuesday. Stephens reaffirmed an "overweight" rating and issued a $14.00 target price on shares of 10x Genomics in a research report on Thursday. Morgan Stanley reduced their price target on shares of 10x Genomics from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Friday, February 14th. Barclays dropped their price objective on shares of 10x Genomics from $15.00 to $12.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Finally, Canaccord Genuity Group cut their price objective on shares of 10x Genomics from $18.00 to $15.00 and set a "buy" rating on the stock in a research report on Monday. One analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat, 10x Genomics presently has a consensus rating of "Hold" and a consensus target price of $16.42.

Insider Buying and Selling

In related news, CEO Serge Saxonov sold 5,092 shares of 10x Genomics stock in a transaction on Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $56,368.44. Following the transaction, the chief executive officer now directly owns 879,482 shares in the company, valued at $9,735,865.74. The trade was a 0.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Alan Mateo bought 40,000 shares of the business's stock in a transaction dated Friday, February 21st. The shares were bought at an average cost of $11.14 per share, for a total transaction of $445,600.00. Following the completion of the transaction, the director now directly owns 61,691 shares of the company's stock, valued at $687,237.74. This trade represents a 184.41% increase in their ownership of the stock. The disclosure for this purchase can be found here. 9.39% of the stock is owned by corporate insiders.

10x Genomics Price Performance

Shares of NASDAQ TXG traded up $0.19 during mid-day trading on Friday, reaching $9.39. 3,013,323 shares of the company traded hands, compared to its average volume of 2,361,074. 10x Genomics, Inc. has a fifty-two week low of $6.78 and a fifty-two week high of $26.18. The firm has a market cap of $1.15 billion, a PE ratio of -6.18 and a beta of 1.94. The stock has a fifty day simple moving average of $8.80 and a 200-day simple moving average of $12.41.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.09. 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. The firm had revenue of $154.88 million during the quarter, compared to analyst estimates of $131.91 million. During the same period last year, the company posted ($0.50) EPS. The firm's quarterly revenue was down 2.3% on a year-over-year basis. As a group, analysts predict that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.